ライフサイエンスコーパス: histocompatibility antigen

1 irteen-residue, maternally transmitted minor histocompatibility antigen.

2 acid early transcript (Rae1) and H-60 minor histocompatibility antigen.

3 this issue employed the redesign of a minor histocompatibility antigen.

4 t the LIMS1 locus appeared to encode a minor histocompatibility antigen.

5 oligoclonal, pointing to a response to minor histocompatibility antigens.

6 ens, although they remained tolerant to host histocompatibility antigens.

7 -specific differentiation antigens and minor histocompatibility antigens.

8 r major histocompatibility antigens or minor histocompatibility antigens.

9 ic antigen-presenting cells presenting minor histocompatibility antigens.

10 the development of humoral immunity to minor histocompatibility antigens.

11 d by donor T cells that recognize host minor histocompatibility antigens.

12 n mismatching for cellular peptides known as histocompatibility antigens.

13 affected tissues and giving rise to multiple histocompatibility antigens.

14 ammation and up-regulation of class I and II histocompatibility antigens.

15 iated with sensitization to mismatched donor histocompatibility antigens.

16 ts that confront the host with foreign minor histocompatibility antigens.

17 is controlled by genetic factors, especially histocompatibility antigens.

18 in receptor protein 1 (TFRC) and HLA class I histocompatibility antigen A, B and C (HLA-ABC) enabled

19 The hypothesis that ICAM-1 acts as a minor histocompatibility antigen and that anti-ICAM-1 antibodi

20 ells in the glands; 4) upregulation of major histocompatibility antigens and adhesive molecules by ep

21 regulate surface expression of class I major histocompatibility antigens and also inhibit tumor necro

22 that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to h

23 o operational tolerance to the donor's major histocompatibility antigens and long-term acceptance to

24 vances in systematic identification of minor histocompatibility antigens and neoantigens arising from

25 on of Tregs against major and possibly minor histocompatibility antigens and predict the feasibility

26 and subsequent reduced presentation of minor histocompatibility antigens and reduced ligation of acti

27 nt is acquired tolerance of allogeneic minor histocompatibility antigens and that posttransplant immu

28 rolling the production of antibodies against histocompatibility antigens are of prime importance in o

29 Immune responses to minor histocompatibility antigens are poorly understood and pr

30 ong MHC matched mouse strains, a few unknown histocompatibility antigens are targeted by the cytotoxi

31 the ubiquitous light chain of class I major histocompatibility antigens, as the amyloid fibril prote

32 d the shared antigens do not represent minor histocompatibility antigens, as their sequences are iden

33 orescence intensity [aMFI] >= 1000), a minor histocompatibility antigen, associated with graft failur

34 RHGDIB) (adjusted MFI [aMFI]>=1000), a minor histocompatibility antigen, associated with graft failur

35 ry pathway which reduces expression of major histocompatibility antigens at the plasma membrane and s

36 CD4+ T cell-mediated GVHD across this minor histocompatibility antigen barrier depends on the expres

37 ls (HSCs) when transplanted across the major histocompatibility antigen barriers if transplanted alon

38 ize bone marrow grafts bearing hematopoietic histocompatibility antigens bear surface markers of natu

39 Mismatched histocompatibility antigens between donor organ and host

40 ssion and near to complete mismatch of major histocompatibility antigens between the diabetic cynomol

41 oductive immunology, and how major and minor histocompatibility antigens, blood group antigens, and t

42 ed specific tolerance to both host and donor histocompatibility antigens, but normal anti-third party

43 -deficient CD8(+) T-cell response to a minor histocompatibility antigen by phenotypic and in vivo ima

44 RFX5 cause bare lymphocyte syndrome or major histocompatibility antigen class II deficiency.

45 The major histocompatibility antigen class II-associated invariant

46 Expression of major histocompatibility antigens class-2 (MHC-II) under non-i

47 genes that are not associated with the major histocompatibility antigen complex genes.

48 ficient B6.gld mice as recipients in a Major Histocompatibility Antigen Complex-matched minor Histoco

49 Minor histocompatibility antigens contribute to the control of

50 Here we describe a human minor histocompatibility antigen created by a polymorphism in

51 On the other hand, the importance of minor histocompatibility antigens derived from nonhematopoieti

52 s alloimmune syndrome in recipients of minor histocompatibility antigen disparate donor cells, showin

53 When transplanted into minor histocompatibility antigen-disparate allogeneic recipien

54 radiation chimeras across the multiple minor histocompatibility antigen-disparate, C57BL/6-->BALB.B c

55 urrent dogma dictates that this is driven by histocompatibility antigen disparities between donor and

56 es across a two-haplotype class I plus minor histocompatibility antigen disparity by a 12-d course of

57 ed across a two-haplotype class I plus minor histocompatibility antigen disparity by a 12-day course

58 GVHD and other BMT complications other than histocompatibility antigen disparity.

59 cells that are specific for recipient minor histocompatibility antigens encoded by Y-chromosome gene

60 Allogeneic antibodies against minor histocompatibility antigens encoded on the Y chromosome

61 nor human leukocyte antigen molecules, minor histocompatibility antigens, endothelial cells, RBCs, or

62 epends on an orchestrated immune response to histocompatibility antigens expressed by the grafted tis

63 CAID, but soluble and cell-associated (minor histocompatibility) antigens generated cell-associated A

64 c acid early inducible (RAE-1) and H60 minor histocompatibility antigen genes on mouse chromosome 10

65 c T cell clones specific for the human minor histocompatibility antigen H-Y and restricted by HLA-A*0

66 Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also asso

67 peptide peptidase (SPP), also known as minor histocompatibility antigen H13.

68 mediated by T cells that recognize the minor histocompatibility antigen H60.

69 ted that recipient mismatching for the minor histocompatibility antigen HA-1 is associated with acute

70 For minor histocompatibility antigens HA-1 and HA-2, normal cell e

71 BALB.B spleen cells, despite multiple minor histocompatibility antigen (HA) differences.

72 Indirect presentation of minor histocompatibility antigens (HA) as revealed by cross-pr

73 f alloantibody responses against foreign HLA histocompatibility antigens has never been delineated.

74 rkers (intercellular adhesion molecule-1 and histocompatibility antigen HLA-DR) in arteries and arter

75 ition mediated by Ly-49A in the mouse, human histocompatibility antigen (HLA)-B*2705-specific NK clon

76 to late phase trials and to evaluate closely histocompatibility antigen (HLA)-matched banked antigen-

77 ted with the expression of the class I major histocompatibility antigen, HLA-B27.

78 produces HvG against the male specific minor histocompatibility antigen HY.

79 the "missing self" and not the "hemopoietic histocompatibility antigen" hypothesis for HR.

80 morphic genes are known to encode functional histocompatibility antigens in mismatched individuals, b

81 HLA-B27-restricted CTL response to HY minor histocompatibility antigens in rats and mice transgenic

82 eactive CD4+ lymphocytes responding to major histocompatibility antigens in vivo.

83 ncluding recognition of sex-determined minor histocompatibility antigens, influence of sex hormones o

84 ed by the indirect recognition of allogeneic histocompatibility antigens late in transplantation may

85 CD1 family of evolutionarily conserved major histocompatibility antigen-like molecules, controls the

86 In a single minor histocompatibility antigen (male to female)-dependent ao

87 In addition, a better understanding of minor histocompatibility antigens may lead to more targeted im

88 products induced BMT rejection across minor histocompatibility antigen (mHA) barriers.

89 he immune response to DBY, a model H-Y minor histocompatibility antigen (mHA) in a male patient with

90 grafts supplemented with T cells in a minor histocompatibility antigen (mHA)-mismatched mouse model.

91 in susceptibility to immune pressure, minor histocompatibility antigen (mHa)-specific T-cell lines o

92 Human minor histocompatibility antigens (mHA) and clinically relevan

93 Next, we immunized the donor to the minor histocompatibility antigens (mHA) of the recipient by me

94 Minor histocompatibility antigen (mHag) discordances have been

95 toma in a murine model of MHC-matched, minor histocompatibility antigen (mHAg)-mismatched bone marrow

96 Minor histocompatibility antigens (mHAg's) are peptides encode

97 Minor histocompatibility antigens (mHags) are immunogenic pept

98 D because of the presence of recipient minor histocompatibility antigens (mHAgs) in whole-cell tumor

99 donor T cells that recognize recipient minor histocompatibility antigens (mHAgs) is a potential strat

100 ming of donor T cells against putative minor histocompatibility antigens (mHAgs) on the tumor vaccine

101 Minor histocompatibility antigens (mHAgs) present a significan

102 T cell recognition of minor histocompatibility antigens (mHags) underlies allogeneic

103 T cell alloreactivity against minor histocompatibility antigens (mHAgs)-polymorphic peptides

104 d major histocompatibility complex and minor histocompatibility antigens (mHAgs).

105 imarily by donor T-cell recognition of minor histocompatibility antigens (mHAgs).

106 Minor histocompatibility antigens (mHAs) are known targets of

107 lloreactive donor T cells against host minor histocompatibility antigens (mHAs) cause graft-versus-ho

108 In contrast, the implication of minor histocompatibility antigens (mHAs) in AMR has not been f

109 increased rejection is likely against minor histocompatibility antigens (mHAs).

110 ed major HLA disparities or expressing minor histocompatibility antigen (miHA) differences presented

111 rom donors vaccinated against a single minor histocompatibility antigen (miHA) expressed by leukemia

112 B6 (H-2(b)) recipients primed to donor minor histocompatibility antigen (MiHA) prior to BM transplant

113 Minor histocompatibility antigen (miHA) vaccines have the pote

114 ed, CD4-driven murine GVHD model and a minor histocompatibility antigen (MiHA)-mismatched, CD8-driven

115 Minor histocompatibility antigen (MiHA)-specific T cells were

116 lloreactive T cell responses targeting minor histocompatibility antigens (MiHA) expressed on malignan

117 nd the interaction of these cells with minor histocompatibility antigen- (miHA-) mismatched CD8+ T ce

118 D8+ stem cell memory T cells targeting minor histocompatibility antigens (MiHAs) expressed by recipie

119 itude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients with sel

120 tiate GVHD by directly presenting host minor histocompatibility antigens (miHAs) to donor CD8 cells.

121 izing polymorphic peptides, designated minor histocompatibility antigens (MiHAs), that are presented

122 ing tumor-specific antigens (TSAs) and minor histocompatibility antigens (MiHAs).

123 nd recipient were incompatible at many minor histocompatibility antigens (minor H Ags), the CD8 T-cel

124 Minor histocompatibility antigens (minor H antigens) are targe

125 dent GVHD in a mouse model across only minor histocompatibility antigens (minor H antigens).

126 en Rux-chow was fed to C.B10 mice in a minor histocompatibility antigen mismatched (B6 C.B10) AA mode

127 Major histocompatibility antigens mismatched between donor and

128 In minor histocompatibility-antigen mismatched allogeneic heart g

129 the role of donor Stat1 in MHC-matched minor histocompatibility antigen-mismatched (mHA-mismatched) a

130 the mechanisms of DLI in MHC-matched, minor histocompatibility antigen-mismatched allogeneic chimera

131 compatibility complex-matched multiple minor histocompatibility antigen-mismatched alloHCT using bone

132 may not apply to MHC-matched, multiple minor histocompatibility antigen-mismatched alloSCT, the most

133 In both a minor histocompatibility antigen-mismatched as well as a MHC-h

134 Recipients were H-2-matched, minor histocompatibility antigen-mismatched C57BL/6 mice with

135 ngle Y chromosome-encoded, or multiple minor histocompatibility antigen-mismatched hematopoietic cell

136 ocompatibility Antigen Complex-matched minor Histocompatibility Antigen-mismatched murine model for G

137 ets, and we report that transfusion of minor histocompatibility antigen-mismatched platelets induced

138 n important role in clinical GVHD in a minor histocompatibility antigen-mismatched setting.

139 histocompatibility complex-matched and minor histocompatibility antigen-mismatched unrelated donors a

140 usions (DLIs) were incorporated into a minor histocompatibility antigen-mismatched, T cell-depleted,

141 histocompatibility complex (MHC) and non-MHC-histocompatibility antigen (non-MHC-HA) barriers.

142 The induction of tolerance to the histocompatibility antigens of the organ donor in the lo

143 ntation, donors' T cells can recognize minor histocompatibility antigens on recipient cells and gener

144 o be mediated by T-cell recognition of minor histocompatibility antigens on recipient cells.

145 The only known polymorphic histocompatibility antigens on the fetal trophoblast are

146 by increased recipient mismatching for major histocompatibility antigens or minor histocompatibility

147 The inclusion of SNPs that encode minor histocompatibility antigens or other genetic polymorphis

148 cagon receptor, a ras-related protein (Rad), histocompatibility antigens, PC-1, and fatty acid bindin

149 Minor histocompatibility antigens play a significant role in a

150 (TCR) to peptide antigen presented by major histocompatibility antigens (pMHC) on antigen-presenting

151 when recipient lymphocytes encounter foreign histocompatibility antigens presented by the graft's end

152 ymes to cleavage sites and of class II major histocompatibility antigen-presenting proteins to helper

153 s that humoral and cellular sensitization to histocompatibility antigens prior to and after islet tra

154 Donor-recipient mismatches in histocompatibility antigens recognized by lymphoid cells

155 poorly defined minor (i.e., other than HLA) histocompatibility antigens remains a serious problem in

156 The GVL effect is directed against minor histocompatibility antigens shared by normal and leukemi

157 tly suppressed the clonal expansion of minor histocompatibility antigen-specific CD8 T cells during t

158 cells do not inhibit allogeneic MHC or minor histocompatibility antigen-specific CTL production), dep

159 arrow is not matched in the clinic for minor histocompatibility antigens, such as those carried by pl

160 murine model that uses differences in minor histocompatibility antigens to generate Scl GVHD.

161 , skin differing from the host only by minor histocompatibility antigens undergoes slower (i.e., chro

162 d donor MHC class I and II, and of H-Y minor histocompatibility antigen was assessed by quantifying p

163 d bone marrow, mismatched for multiple minor histocompatibility antigens, was induced in Fas mutant a

164 with a response to immunodominant host minor histocompatibility antigens, we detected oligoclonal liv

165 sparities in cytoplasmically inherited minor histocompatibility antigens, we examined one hypervariab

166 ng genetic disparity in both major and minor histocompatibility antigens were used for transplantatio

167 Thus, the male-specific H-Y histocompatibility antigen, which is ubiquitously expres

168 ion of these hematopoietically derived minor histocompatibility antigens will induce significant graf

169 Minor histocompatibility antigens with expression restricted t